Company: SCLXW
Filing Date: 2025-12-16
Form Type: S-1
Source: 0001193125-25-319720
Chunk: 613

Company: Scilex Holding Co
Filing Date: 2025-12-16
Form: S-1
Chunk 613
---
alty Purchase Agreement shall terminate six months following receipt by the Gloperba-Elyxyb RPA Purchasers of all payments of the Gloperba-Elyxyb Purchased Receivables to which each Gloperba-Elyxyb RPA Purchaser is entitled during the Gloperba-Elyxyb Payment Term. The Company elected the fair value option for the Gloperba-Elyxyb Royalty Purchase Agreement and records the changes in the fair value within the unaudited condensed consolidated statements of operations at the end of each reporting period. As of each of February 28, 2025 and September 30, 2025, the fair value of the Gloperba-Elyxyb Royalty Purchase Agreement was $ 0.5 million and $ 1.5million, recorded as a purchased revenue liability on the unaudited condensed consolidated balance sheet.

|                                                     |     | September 30,2025 |       |   |
|:----------------------------------------------------|:----|:------------------|------:|:--|
| Beginning Balance as of February 28, 2025           |     | $                 |   500 |   |
| Repayment of purchased revenue liability            |     | $                 |   (41 | ) |
| Change in fair value of purchased revenue liability |     |                   | 1,041 |   |
| Ending Balance as of September 30, 2025             |     | $                 | 1,500 |   |

8. Sorrento Stock Purchase Agreement Sorrento Stock Purchase Agreement On September 21, 2023, the Company entered into that certain Stock Purchase Agreement (the “Sorrento SPA”) with Sorrento Therapeutics, Inc. (“Sorrento”), the Company’s then-controlling stockholder, pursuant to which the Company purchased from Sorrento (i) 1,716,245shares of Common Stock, (ii) 29,057,097shares of Series A Preferred Stock, par value $ 0.0001per share (the “Series A Preferred Stock”), and (iii) 1,386,617Public Warrants (as defined below), which are currently exercisable for an aggregate of up to 39,617shares of Common Stock and 3,104,000Private Warrants (collectively, the “Purchased Securities”), which are currently exercisable for an aggregate of up to 88,685shares of Common Stock. As a result, Sorrento no